Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Glenn Phillips

Showing results (11-20 of 43) with videos related to

Pageof 5
Sort By:
Health Affairs Scholar|July 28, 2025
What drug characteristics explain the wide range of manufacturer rebates?Molly T Beinfeld, Fariel LaMountain, Glenn Phillips, et al.
Muscle & Nerve|December 19, 2024
The Economic Burden of Myasthenia Gravis (MG): A Survey of Affected People and Their FamiliesKathleen Yoder, Rachael Burris, Sujatha Gurunathan, et al.
Frontiers in Neurology|February 4, 2022
Real-World Healthcare Resource Utilization and Cost Burden Assessment for Adults With Generalized Myasthenia Gravis in the United StatesGlenn Phillips, Catarina Abreu, Amit Goyal, et al.
Multiple Sclerosis and Related Disorders|January 21, 2017
Impact of daclizumab versus interferon beta-1a on patient-reported outcomes in relapsing-remitting multiple sclerosisYing Liu, Timothy Vollmer, Eva Havrdova, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|February 17, 2017
Validity of the timed 25-foot walk as an ambulatory performance outcome measure for multiple sclerosisRobert W Motl, Jeffrey A Cohen, Ralph Benedict, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|February 17, 2017
The Nine-Hole Peg Test as a manual dexterity performance measure for multiple sclerosisPeter Feys, Ilse Lamers, Gordon Francis, et al.
BMC Medical Research Methodology|September 15, 2012
Construct validity of 2 measures to assess reasons for antipsychotic discontinuation and continuation from patients' and clinicians' perspectives in a clinical trialDouglas Faries, Haya Ascher-Svanum, Glenn Phillips, et al.
Journal of Neurology|July 10, 2016
Development of the multiple sclerosis (MS) early mobility impairment questionnaire (EMIQ)Tjalf Ziemssen, Glenn Phillips, Ruchit Shah, et al.
Multiple Sclerosis and Related Disorders|November 2, 2018
Multiple sclerosis relapse: Qualitative findings from clinician and patient interviewsLouis S Matza, Katherine Kim, Glenn Phillips, et al.
Journal of the Neurological Sciences|October 19, 2024
Post-hoc analyses from the ADAPT clinical study demonstrate aggregate sustained benefit of Efgartigimod in generalized myasthenia gravisSarah Dewilde, Alison Griffiths, Cynthia Z Qi, et al.
Pageof 5

Showing results (11-20 of 43) with videos related to

Sort By:
Pageof 5
Health Affairs Scholar|July 28, 2025
What drug characteristics explain the wide range of manufacturer rebates?Molly T Beinfeld, Fariel LaMountain, Glenn Phillips, et al.
Muscle & Nerve|December 19, 2024
The Economic Burden of Myasthenia Gravis (MG): A Survey of Affected People and Their FamiliesKathleen Yoder, Rachael Burris, Sujatha Gurunathan, et al.
Frontiers in Neurology|February 4, 2022
Real-World Healthcare Resource Utilization and Cost Burden Assessment for Adults With Generalized Myasthenia Gravis in the United StatesGlenn Phillips, Catarina Abreu, Amit Goyal, et al.
Multiple Sclerosis and Related Disorders|January 21, 2017
Impact of daclizumab versus interferon beta-1a on patient-reported outcomes in relapsing-remitting multiple sclerosisYing Liu, Timothy Vollmer, Eva Havrdova, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|February 17, 2017
Validity of the timed 25-foot walk as an ambulatory performance outcome measure for multiple sclerosisRobert W Motl, Jeffrey A Cohen, Ralph Benedict, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|February 17, 2017
The Nine-Hole Peg Test as a manual dexterity performance measure for multiple sclerosisPeter Feys, Ilse Lamers, Gordon Francis, et al.
BMC Medical Research Methodology|September 15, 2012
Construct validity of 2 measures to assess reasons for antipsychotic discontinuation and continuation from patients' and clinicians' perspectives in a clinical trialDouglas Faries, Haya Ascher-Svanum, Glenn Phillips, et al.
Journal of Neurology|July 10, 2016
Development of the multiple sclerosis (MS) early mobility impairment questionnaire (EMIQ)Tjalf Ziemssen, Glenn Phillips, Ruchit Shah, et al.
Multiple Sclerosis and Related Disorders|November 2, 2018
Multiple sclerosis relapse: Qualitative findings from clinician and patient interviewsLouis S Matza, Katherine Kim, Glenn Phillips, et al.
Journal of the Neurological Sciences|October 19, 2024
Post-hoc analyses from the ADAPT clinical study demonstrate aggregate sustained benefit of Efgartigimod in generalized myasthenia gravisSarah Dewilde, Alison Griffiths, Cynthia Z Qi, et al.
Pageof 5